Ifabotuzumab
(anti-EphA3)
Recombinant Monoclonal Antibody for the Treatment of cancers
Ifabotuzumab is a first-in-class, monoclonal antibody targeting the EphA3 receptor tyrosine kinase created using Humanigen’s proprietary Humaneered® technology.
Ifabotuzumab is a first-in-class, monoclonal antibody targeting the EphA3 receptor tyrosine kinase created using Humanigen’s proprietary Humaneered® technology.
Ifabotuzumab is unique in its potential to attack tumors at their source by killing tumor cells, tumor stromal cells that protect them, and the vasculature that feeds them without killing normal cells. This unique combination of activities may provide the potential to generate durable responses. Ifabotuzumab may have a similar mechanism of action in patients with solid tumors since it targets solid tumor stem cells and their microenvironment.